Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 2
Submit an article Journal homepage
762
Views
11
CrossRef citations to date
0
Altmetric
Review

Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia

Maria GavriatopoulouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, GreeceView further author information
,
Evangelos TerposDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, GreeceView further author information
,
Efstathios KastritisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, GreeceView further author information
&
Meletios A. DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, GreeceCorrespondence[email protected]
View further author information
Pages 197-205 | Received 15 Jul 2016, Accepted 19 Dec 2016, Published online: 03 Jan 2017

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Andrew R. Branagan, Mathew Lei, Steven P. Treon & Jorge J. Castillo. (2021) Clinical application of genomics in Waldenström macroglobulinemia. Leukemia & Lymphoma 62:8, pages 1805-1815.
Read now
Yan-Hua Zheng, Li Xu, Chun Cao, Juan Feng, Hai-Long Tang, Mi-Mi Shu, Guang-Xun Gao & Xie-Qun Chen. (2019) Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis. OncoTargets and Therapy 12, pages 2751-2766.
Read now

Articles from other publishers (9)

Eirini Solia, Meletios A. Dimopoulos & Efstathios Kastritis. (2023) Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America 37:4, pages 689-705.
Crossref
Jingjing Zhu, Xinyu Zhu, Fengyang Xie, Yi Ding, Huina Lu, Yan Dong, Ping Li, Jianfei Fu, Aibin Liang, Yu Zeng & Bing Xiu. (2023) Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors. Pathology and Oncology Research 29.
Crossref
Qin Cao, Huimeng Qi, Li Yao & Qiang Liu. (2020) Monoclonal gammopathy of renal significance: clinical manifestation, pathogenic characteristic and treatment. Panminerva Medica 62:1.
Crossref
Alessandra Tedeschi, Concetta Conticello, Rita Rizzi, Giulia Benevolo, Luca Laurenti, Maria Teresa Petrucci, Francesco Zaja & Marzia Varettoni. (2018) Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. Hematological Oncology 37:2, pages 117-128.
Crossref
Osnat Bairey & Tali Siegal. (2018) The possible role of maintenance treatment for primary central nervous system lymphoma. Blood Reviews 32:5, pages 378-386.
Crossref
Haiyang Chen, Peiran Song, Yanyan Diao, Yongjia Hao, Dou Dou, Wanqi Wang, Xiaoyu Fang, Yanling Wang, Zhenjiang Zhao, Jian Ding, Honglin Li, Hua Xie & Yufang Xu. (2018) Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors. MedChemComm 9:4, pages 697-704.
Crossref
An-Guor WangAn-Guor Wang. 2018. Emergency Neuro-ophthalmology. Emergency Neuro-ophthalmology 327 331 .
Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson & Paul G. Richardson. (2017) The proteasome and proteasome inhibitors in multiple myeloma. Cancer and Metastasis Reviews 36:4, pages 561-584.
Crossref
Nora S Sánchez, Gordon B Mills & Kenna R Mills Shaw. (2017) Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics 18:16, pages 1525-1539.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.